Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).
about
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisNelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotesCost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinentAntimonial resistance in Leishmania donovani is associated with increased in vivo parasite burdenMultiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencingIn vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasitesDrug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasisLeishmania donovani develops resistance to drug combinationsFitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania majorDrug resistance in leishmaniasisDrug resistance in eukaryotic microorganisms.Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stressIn vitro and in vivo interactions between miltefosine and other antileishmanial drugsStructures, targets and recent approaches in anti-leishmanial drug discovery and development.Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug effluxIn Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral CandidiasisIn Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.Novel Agents against Miltefosine-Unresponsive Leishmania donovani.The relationship between leishmaniasis and AIDS: the second 10 yearsMiltefosine--discovery of the antileishmanial activity of phospholipid derivatives.Possible mechanism of miltefosine-mediated death of Leishmania donovani.Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.Genomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovaniAttenuation and Production of the Amphotericin B-Resistant Leishmania tropica StrainTreatment of leishmaniasis with miltefosine: 2008 status.Drug resistance in visceral leishmaniasis.The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani.Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.Drug resistance in leishmaniasis: Newer developments.Glycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery.Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis.Therapy of vector-borne protozoan infections in nonendemic settings.Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives.Flavone-resistant Leishmania donovani overexpresses LdMRP2 transporter in the parasite and activates host MRP2 on macrophages to circumvent the flavone-mediated cell death.Cutaneous leishmaniasis: therapeutic strategies and future directions.Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art.Chemotherapy of leishmaniasis: present challenges.Evaluating drug resistance in visceral leishmaniasis: the challenges.Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro.
P2860
Q28271849-F754C458-23EC-4774-B6F7-C67C0C5BF50CQ28473470-732DD469-CF2A-46BC-BC4B-6E2C08214847Q28475431-670D73C7-0445-4116-9009-91B0E37EAF84Q28476400-CC75933E-7859-49CD-89C0-5ABBF9736434Q28480626-292EDB19-ADE0-47CB-AFF6-97BEA14565FCQ28482212-27D62666-5F31-4610-B4CE-9280DC9C2288Q28483875-95B2361F-129A-4457-BE93-EC51DCC12F7EQ28484463-BFA6AC7E-C9B1-4879-A965-278DBAE47040Q28546940-E6AA85AE-2EF0-4AB5-BC2D-66AE0D0027FBQ29616242-67BD5875-F835-4740-AEC6-794C97E89CB7Q30248243-AA4CF632-C7C0-4676-97D2-2BD48D87C34FQ33797614-5AEB0AAB-64F3-4458-8142-B15E13EA1CD1Q34301638-7B5A8240-E570-4AA4-91AB-8612E8D314D1Q35012968-9A9D7503-23CF-4B47-A5AE-807B4DD1EC99Q35023368-4AA5E231-E416-4A77-A595-FAEEEC3BFCDBQ35791192-31A398B8-A408-4D07-9A64-26F84BF0DAFCQ35859984-033F9077-84B4-4278-AE55-C1524977FE36Q36290836-973B8B73-A1F5-471B-BAE3-D53BD9893C50Q36538814-2D6B0222-D8C0-4187-ADA2-601348C839C4Q36564101-35E4C709-A3BB-45B1-92BF-E74544828CEBQ36669276-03C1953C-B35E-49F7-8519-2B227F51644DQ36803937-1E06FA01-F392-4C11-873B-8B4933043A28Q37023262-4B7F3B37-4404-4448-9E7E-DF41356B7A5BQ37232181-609613B2-C1E7-4142-BFF4-CFCC728FA335Q37249719-A2517BEC-C061-408A-B7BA-596F3217CB8EQ37407549-0F7BC4DE-12E1-47CB-91C7-25DEB253E6A8Q37425218-A07B3CCC-8DE7-4B5E-9885-B83775591092Q37465295-8EEAABA5-0E0C-4DBF-9C6C-220F6ECA27C0Q37615730-EB063FC3-D13C-413C-A5A3-F325A6FD9F51Q37712190-12F8217A-020B-4793-948F-D52961409DB4Q37763950-B6434733-C70E-4DE8-94E8-63BDD1308613Q37811110-B722649A-7B50-4FA2-B453-89F067ED53F4Q37879203-71183705-F6AC-4F98-8880-3AD4BB90B787Q38154347-50FFEE04-FB8B-41DE-9990-C855082265E8Q38307939-A4E2418F-F5C7-42DA-A1F2-6621063394A2Q38872459-D58D61EF-5A69-4A20-A3A9-E361C736E539Q38939544-3DC96BBF-2DD4-45A5-A6D7-EC7A262304FAQ39011875-BE0571DD-1E3A-4B0B-9671-908A91474CDCQ39014583-8A72A48D-934A-4482-B02E-8018AF0C8456Q39078243-E7CB7766-1AE6-40F6-ABE7-B61E57332F56
P2860
Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Characterisation of Leishmania ...... lphosphocholine (miltefosine).
@en
Characterisation of Leishmania ...... ant to hexadecylphosphocholine
@nl
type
label
Characterisation of Leishmania ...... lphosphocholine (miltefosine).
@en
Characterisation of Leishmania ...... ant to hexadecylphosphocholine
@nl
prefLabel
Characterisation of Leishmania ...... lphosphocholine (miltefosine).
@en
Characterisation of Leishmania ...... ant to hexadecylphosphocholine
@nl
P2093
P1476
Characterisation of Leishmania ...... lphosphocholine (miltefosine).
@en
P2093
F Javier Pérez-Victoria
Karin Seifert
Sangeeta Matu
Santiago Castanys
Simon L Croft
P304
P356
10.1016/S0924-8579(03)00125-0
P577
2003-10-01T00:00:00Z